Inventaire - teman dan komunitas anda adalah perpustakaan terbaik

FRAX(®) with and without bone mineral density

pengarang

William D. Leslie

Eugene V McCloskey

Anders Odén

John Kanis

Helena Johansson

diterbitkan dalam: Calcified Tissue International

tanggal publikasi: 2011-11-06

bahasa: Inggris

Cites articles 39

Date

Judul

Pengarang

2010-07-26

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

Jeffrey R Curtis
2010-11-23

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

Suzanne N Morin, Angela M. Cheung, William D. Leslie
2010-04-01

Filtering FRAX.
2010-05-20

FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example
2010-06-18

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

Eugene V McCloskey, Anders Odén, John Kanis, Helena Johansson
2010-03-19

The US FRAX filter: avoiding confusion or hindering progress?

Cyrus Cooper
2009-11-19

Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores

Carol Coupland, Julia Hippisley-Cox
2009-02-03

FRAX and its applications to clinical practice

Eugene V McCloskey, Anders Odén, John Kanis, Helena Johansson
2009-02-28

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Eugene V McCloskey, Anders Odén, John Kanis, Helena Johansson
2009-06-30

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

Kurt Lippuner, Jane A. Cauley, Dennis M Black, Steven R Cummings, Richard Eastell, Steven Boonen, HORIZON Pivotal Fracture Trial, Lisa Palermo, Silvano Adami, Dieter Felsenberg
2009-03-17

BMD, clinical risk factors and their combination for hip fracture prevention
2008-04

FRAX and the assessment of fracture probability in men and women from the UK
2008-02-22

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)
2008-11-14

The incidence and risk of hip fracture in Poland
2008-10-01

Health economics of osteoporosis
2008-01-01

Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.

Jane A. Cauley, Kay-Tee Khaw, Elizabeth Barrett-Connor, Kristine Ensrud, Lori Mosca
2008-11-11

Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study
2008-06-10

A revised clinician's guide to the prevention and treatment of osteoporosis.
2008-02-22

Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA.

Sundeep Khosla, Anna N. A. Tosteson, L. Joseph Melton
2007-02-24

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women

Cyrus Cooper, Jonathan Reeve, Kerrie M. Sanders, Anne-Marie Schott, David J. Torgerson, Tjeerd P van Staa, L. Joseph Melton
2007-10-30

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

Michael McClung
2007-03-01

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis

Sarah Davis
2006-04-05

Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors

Jean-Yves Reginster, Patrice Fardellone
2006-03-24

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
2004-07-23

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture
2004-01-19

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

Peter Selby, Eugene V McCloskey, John Kanis, Monique Beneton, Tarja Jalava, Liisa Pylkkanen, Karthik Kayan, Sakari Aropuu
2004-02-16

Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study

John Kanis, Dennis M Black, Olof Johnell
2003-03-01

Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial

Kay-Tee Khaw
2003-09-01

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

John Kanis, Dennis M Black, Olof Johnell
2003-01-01

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis
2002-07-17

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Charles Kooperberg, Rebecca D. Jackson, Barbara V Howard, Shirley A A Beresford, Marcia L. Stefanick, Andrea LaCroix, Judith K. Ockene
2002-07

International variations in hip fracture probabilities: implications for risk assessment

Anders Odén, John Kanis, Olof Johnell

Artikel - wd:Q37953297

Selamat datang di Inventaire

perpustakaan teman-teman dan komunitas anda

pelajari lebih lanjut